The Missing Data: Why We Need Better Information on NK Cell Therapy for Kids with GVHD

Background: Allogeneic hematopoietic cell transplantation (HCT) is a curative intent therapy for many pediatric life-threatening conditions but is significantly limited by graft-versus-host disease (GVHD). Natural Killer (NK) cell-based immunotherapy represents a promising frontier for preventing or treating GVHD, yet the landscape of dedicated pediatric clinical research in this area remains poorly defined. Methods: To evaluate the clinical trial activity for NK cell therapies in pediatric GVHD, we conducted a comprehensive search of ClinicalTrials.gov on July ۵, ۲۰۲۵. We identified interventional studies specifically investigating NK cell infusions for GVHD in pediatric populations. Results: Our initial search yielded only four international trials. Upon detailed review of eligibility and enrollment data, one study was excluded for lacking pediatric participants. Of the three remaining trials that enrolled pediatric patients, none had resulting data publicly available on ClinicalTrials.gov or through published manuscripts on PubMed or google scholar. This critical gap prevents any assessment of safety, efficacy, or feasibility outcomes for NK cell therapy in this vulnerable population. Conclusion: There is a profound scarcity of clinical research and a critical lack of data reporting for NK cell therapies in pediatric GVHD. The absence of publicly available results from completed trials severely hinders scientific progress and clinical application. This review highlights this urgent unmet need and calls for a concerted effort to prioritize robust, well-reported pediatric trials and ensure the timely dissemination of their findings to guide future therapeutic strategies.